Eli Lilly 2013 Annual Report Download - page 88

Download and view the complete annual report

Please find page 88 of the 2013 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 160

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160

74
74
2013 2012 2011
Segment revenue—to unaffiliated customers:
Human pharmaceutical products:
Endocrinology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 7,304.4 $ 6,810.9 $ 6,806.7
Neuroscience . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,216.2 7,575.1 9,723.8
Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,268.5 3,281.6 3,322.2
Cardiovascular . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,923.2 2,632.5 2,486.4
Other pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249.3 266.8 268.8
Total human pharmaceutical products . . . . . . . . . . . . . . . . . . . . . . 20,961.6 20,566.9 22,607.9
Animal health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,151.5 2,036.5 1,678.6
Total segment revenue. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 23,113.1 $ 22,603.4 $ 24,286.5
Segment profits(1):
Human pharmaceutical products . . . . . . . . . . . . . . . . . . . . . . . . . $ 5,015.0 $ 4,393.4 $ 5,837.9
Animal health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 556.6 508.1 301.0
Total segment profits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 5,571.6 $ 4,901.5 $ 6,138.9
Reconciliation of total segment profits to consolidated income
before taxes:
Segment profits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 5,571.6 $ 4,901.5 $ 6,138.9
Other profits (losses):
Income related to termination of the exenatide collaboration
with Amylin (Note 4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 495.4 787.8 —
Acquired in-process research and development (Notes 3 and 4) (57.1) — (388.0)
Asset impairment, restructuring, and other special charges
(Note 5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (120.6) (281.1) (401.4)
Total consolidated income before taxes . . . . . . . . . . . . . . . . . . . . . . $ 5,889.3 $ 5,408.2 $ 5,349.5
1 Human pharmaceutical products segment profit includes total depreciation and amortization expense of $1.35 billion, $1.37 billion, and
$1.30 billion for the years ended December 31, 2013, 2012, and 2011, respectively. Animal health segment profit includes total
depreciation and amortization expense of $99.4 million, $91.1 million, and $78.1 million for the years ended December 31, 2013, 2012,
and 2011, respectively.
For internal management reporting presented to the chief operating decision maker, certain costs are fully
allocated to our human pharmaceutical products segment and therefore are not reflected in the animal health
segment's profit. Such items include costs associated with treasury-related financing, global administrative
services, certain acquisition-related transaction costs, and manufacturing variances.
2013 2012 2011
Geographic Information
Revenue—to unaffiliated customers(1):
United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 12,889.7 $ 12,313.1 $ 12,977.2
Europe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,338.4 4,259.7 5,290.9
Japan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,063.8 2,246.2 2,104.1
Other foreign countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,821.2 3,784.4 3,914.3
Revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 23,113.1 $ 22,603.4 $ 24,286.5
Long-lived assets(2):
United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 4,649.6 $ 5,064.7 $ 5,485.3
Europe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,469.7 2,281.1 2,220.2
Japan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81.1 101.5 102.9
Other foreign countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,540.9 1,543.2 1,564.0
Long-lived assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 8,741.3 $ 8,990.5 $ 9,372.4
1 Revenue is attributed to the countries based on the location of the customer.
2 Long-lived assets consist of property and equipment and certain sundry assets.